{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:39Z","timestamp":1791632259214,"version":"4.3.4"},"reference-count":31,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023833","name":"World Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,2,28]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The very early diagnosis of systemic sclerosis (VEDOSS) criteria were developed to diagnose systemic sclerosis (SSc) at a very early stage. However, several studies have applied these criteria inconsistently, often using them to identify patients at a predisease stage. This use has created confusion between the concept of VEDOSS and pre-SSc. With growing interest in predisease states in autoimmunity, a consensus definition of pre-SSc is mandatory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>As a preliminary step towards such definition, this scoping review aimed to map existing definitions of pre-SSc and VEDOSS in the literature, identify item combinations used and capture conceptual variations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines, PubMed and Web of Science were searched using the terms \u2018VEDOSS\u2019 OR \u2018very early diagnosis of systemic sclerosis\u2019 OR \u2018pre-scleroderma\u2019 OR \u2018pre-systemic sclerosis\u2019 OR \u2018pre-SSc\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 106 records screened, 40 full texts were included (eight on pre-SSc and 32 on VEDOSS). Most articles (80%) originated from Europe. Three distinct definitions of pre-SSc were identified, alongside 13 different applications of VEDOSS criteria. Although 62.5% of studies cited the 2011 VEDOSS consensus, only 31.3% applied the complete definition incorporating the three step 1 essential items and step 2 confirmation tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This scoping review highlights the variability of the definitions of VEDOSS and pre-SSc that have been used in the literature. The absence of a consensus definition for pre-SSc contributes to overlapping and blurring boundaries between these concepts. A consensus effort is warranted to select a core set of items for a standardised definition of pre-SSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006716","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:35:13Z","timestamp":1777919713000},"page":"e006716","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Scoping literature review on applied definitions of very early diagnosis of systemic sclerosis (VEDOSS) and pre-systemic sclerosis in original articles"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8558","authenticated-orcid":false,"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[{"name":"Inserm, EHESP, Irset -Institut de Recherche en Sant\u00e9, Environnement et Travail-UMRS, University of Rennes, CHU Rennes, Rennes, France"},{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA"},{"name":"Internal Medicine and Clinical Immunology, CHU Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"INSERM U1016 UMR 8104, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-2283","authenticated-orcid":false,"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Denton","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Division of Medicine, Royal Free Campus, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-3161","authenticated-orcid":false,"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Unit of Immunology, Rheumatology, Allergy and Rare diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy"},{"name":"Vita-Salute, San Raffaele University, Milan, Italy"},{"name":"Inflammation Fibrosis and Ageing Initiative, (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bellando-Randone","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, AOUC, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026050411350762000_12.2.e006716.1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","article-title":"New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine","volume":"30","author":"Lescoat","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"2026050411350762000_12.2.e006716.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24038"},{"key":"2026050411350762000_12.2.e006716.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2026050411350762000_12.2.e006716.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430"},{"key":"2026050411350762000_12.2.e006716.5","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026050411350762000_12.2.e006716.6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard-2023-224211","article-title":"Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease","volume":"84","author":"Deane","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026050411350762000_12.2.e006716.7","first-page":"04560","article-title":"From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosis","volume":"S0003-4967","author":"Lescoat","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026050411350762000_12.2.e006716.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.136929"},{"key":"2026050411350762000_12.2.e006716.9","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00244-7"},{"key":"2026050411350762000_12.2.e006716.10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/23971983221129211","article-title":"Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease","volume":"8","author":"Lescoat","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"2026050411350762000_12.2.e006716.11","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30038-4"},{"key":"2026050411350762000_12.2.e006716.12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00212-6"},{"key":"2026050411350762000_12.2.e006716.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308743"},{"key":"2026050411350762000_12.2.e006716.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02649-1"},{"key":"2026050411350762000_12.2.e006716.15","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"2026050411350762000_12.2.e006716.16","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69"},{"key":"2026050411350762000_12.2.e006716.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"2026050411350762000_12.2.e006716.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2026050411350762000_12.2.e006716.19","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2026050411350762000_12.2.e006716.20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard-2024-226429","article-title":"Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis","volume":"84","author":"Lescoat","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026050411350762000_12.2.e006716.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044765","article-title":"Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol","volume":"11","author":"Lescoat","year":"2021","journal-title":"BMJ Open"},{"key":"2026050411350762000_12.2.e006716.22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/rheumatology\/keae691","article-title":"Systemic sclerosis-related fecal incontinence: a scoping review focusing on a neglected manifestation","volume":"64","author":"Lescoat","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026050411350762000_12.2.e006716.23","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/rheumatology\/keac049","article-title":"Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review","volume":"61","author":"Lescoat","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026050411350762000_12.2.e006716.24","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2026050411350762000_12.2.e006716.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026050411350762000_12.2.e006716.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"2026050411350762000_12.2.e006716.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203716"},{"key":"2026050411350762000_12.2.e006716.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.106302"},{"key":"2026050411350762000_12.2.e006716.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep290"},{"key":"2026050411350762000_12.2.e006716.30","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s10067-020-04973-0","article-title":"Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies","volume":"39","author":"Hamaguchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026050411350762000_12.2.e006716.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.10.004"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:35:15Z","timestamp":1777919715000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2026-006716"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006716","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}